via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Anti-cancer treatments
- Innovative Combination Therapy Shows Promise for Late-Stage Ovarian Cancer
The treatment combined adoptive T-cell therapy with ... from patients to transform into dendritic cells, which then present cancer antigens to killer T cells, activating their anti-tumor responses.
- Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 ...
- Novel photo-oxidation therapy for anticancer treatment
Scientists have achieved a significant breakthrough by inventing a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The ...
- Drug Delivery System May Boost Effects of Anti-Cancer Drug
Subscribe for FREE “At its core, the research is about mitigating some of the critical problems that we face in cancer treatment,” said Zahra Ahmed, lead study author and a Ph.D. student in the Brown ...
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
The Broad Institute is one of the few institutions in the world with such an expansive cancer cell line screening program. By utilizing advanced technologies and global collaborations, the Broad ...
Go deeper with Google Headlines on:
Anti-cancer treatments
[google_news title=”” keyword=”anti-cancer treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CD40
- New Approaches for the Treatment of Lupus Nephritis in the 21st Century
In contrast to the positive signal of CD28/B7 or CD40–CD40L, ligation of PD1 on lymphocytes inhibits B- and T-cell proliferation and cytokine synthesis. PD1 and PDL1 interactions are essential ...
- Advancements In Pancreatic Cancer Treatment: Biotech Innovations And Rising Optimism
Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism . News Group – According to the American Cancer Society in its Cancer ...
- CD40 Ligand Market | New Insight Report Hit Highest Growth Rate by 2030
Global CD40 Ligand Market research report presents facts and figures encompassing manufacturers, types such as [ISF-35, LOAd-700, MEDI-4920] applications [Autoimmune indications, Hepatitis B ...
- This New Experimental Antibody Could Prevent Organ Rejection
An innovative designer antibody attracting attention as a potential treatment for Amyotrophic Lateral Sclerosis (ALS) has successfully prevented rejection of transplanted kidneys in non-human primates ...
- BITT Announces NIH Award for Advancement of Anti-CD40 Antibody
The award for Advancing BITT-101: A Novel Dominant CD40 Antagonist for Use in the Treatment of Sjögren's Syndrome will help support steps toward an IND filing in 2024. "The NIH award will ...
Go deeper with Google Headlines on:
CD40
[google_news title=”” keyword=”CD40″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]